Medical Affairs
Astellas Pharma Europe Ltd. · Daiichi Sankyo · Globus Medical Inc
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
90
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
1
PubMed author-name match
Trials
Studies that name Medical Affairs as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:35 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07602530 · A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical PracticeAstellas Pharma Europe Ltd. · recruiting · Hot Flashes · study director
- N/ANCT07535359 · Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung CancerDaiichi Sankyo · no longer available · SCLC, Extensive-stage Small Cell Lung Cancer · study director
- N/ANCT07455812 · A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During MenopauseAstellas Pharma Europe Ltd. · completed · Hot Flashes · study director
- N/ANCT06741514 · A Study of Precice Intramedullary Limb Lengthening System (IMLL) Limb Lengthening ProceduresNuVasive · enrolling by invitation · Limb Length Discrepancy · study director
- Ph1NCT06648824 · Study of How Mitapivat Affects Midazolam Blood Levels in Healthy ParticipantsAgios Pharmaceuticals, Inc. · completed · Healthy Participants · study chair
- Ph2NCT06369285 · A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerPuma Biotechnology, Inc. · recruiting · Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer · study director
- Ph2NCT06286046 · A Study of Mitapivat in Participants With Sickle Cell Disease and NephropathyAgios Pharmaceuticals, Inc. · withdrawn · Sickle Cell Disease, Nephropathy · study chair
- N/ANCT06279728 · Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC PatientsDaiichi Sankyo · approved for marketing · EGFRm Advanced Non-Small Cell Lung Cancer, EGFRm Metastatic Non-Small Cell Lung Cancer · study director
- Ph4NCT05740371 · Safety of Argatroban Infusion in Conduction DisturbancesTanabe Pharma GmbH · completed · Stable Coronary Artery Disease (CAD), Unstable Angina (Troponin Negative) · study director
- Ph1NCT05610657 · A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic FunctionAgios Pharmaceuticals, Inc. · completed · Moderate Hepatic Impairment · study chair
- Ph1NCT05514249 · Treatment of a Single Patient With CRD-TMH-001Cure Rare Disease, Inc · completed · Duchenne Muscular Dystrophy · study director
- Ph2NCT05490446 · A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)Agios Pharmaceuticals, Inc. · active not recruiting · Myelodysplastic Syndromes · study chair
- N/ANCT05455931 · Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)Kyowa Kirin Pharmaceutical Development Ltd · completed · Mycosis Fungoides and Sézary Syndrome · study director
- Ph1/Ph2NCT05199337 · Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) AmyloidosisK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. · completed · Amyloidosis, AL Amyloidosis · study director
- Ph3NCT05175105 · A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodAgios Pharmaceuticals, Inc. · active not recruiting · Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia · study chair
- Ph3NCT05144256 · A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodAgios Pharmaceuticals, Inc. · active not recruiting · Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia · study chair
- N/ANCT04995315 · Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008Agios Pharmaceuticals, Inc. · completed · Pyruvate Kinase Deficiency · study chair
- N/ANCT04964323 · Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)Agios Pharmaceuticals, Inc. · terminated · Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Anemia · study chair
- N/ANCT04819490 · A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLHKyowa Kirin Pharmaceutical Development Ltd · completed · X-Linked Hypophosphataemia · study director
- Ph3NCT04770753 · A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)Agios Pharmaceuticals, Inc. · active not recruiting · Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia · study chair
- Ph3NCT04770779 · A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Agios Pharmaceuticals, Inc. · active not recruiting · Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia · study chair
- Ph4NCT04677712 · Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock CelluliteEndo USA Inc., a Keenova Therapeutics Company · completed · Edematous Fibrosclerotic Panniculopathy (EFP), Cellulite · study director
- Ph1NCT04472832 · A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult ParticipantsAgios Pharmaceuticals, Inc. · completed · Healthy Volunteers · study chair
- Ph1NCT04145128 · A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian ParticipantsAgios Pharmaceuticals, Inc. · completed · Healthy Volunteers · study chair
- Ph1NCT04128787 · A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881Agios Pharmaceuticals, Inc. · completed · Healthy Volunteers · study chair
- Ph1NCT04015687 · A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy AdultsAgios Pharmaceuticals, Inc. · completed · Healthy Participants · study director
- Ph1NCT03991312 · Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult ParticipantsAgios Pharmaceuticals, Inc. · completed · Healthy Volunteers · study chair
- Ph1NCT03960502 · A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881Agios Pharmaceuticals, Inc. · completed · Healthy Male Participants · study chair
- Ph3NCT03853798 · Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007Agios Pharmaceuticals, Inc. · completed · Pyruvate Kinase Deficiency · study chair
- Ph1NCT03703505 · A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348Agios Pharmaceuticals, Inc. · completed · Healthy Volunteers · study chair
- Ph2NCT03692052 · A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent ThalassemiaAgios Pharmaceuticals, Inc. · active not recruiting · Thalassemia · study chair
- N/ANCT03566407 · Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) PatientsPrometheus Laboratories · terminated · Crohn's Disease · study chair
- Ph3NCT03559699 · A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)Agios Pharmaceuticals, Inc. · completed · Pyruvate Kinase Deficiency, Anemia, Hemolytic · study chair
- Ph3NCT03548220 · A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)Agios Pharmaceuticals, Inc. · completed · Pyruvate Kinase Deficiency, Anemia, Hemolytic · study chair
- N/ANCT03492489 · Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell CarcinomaRegeneron Pharmaceuticals · no longer available · Cutaneous Squamous Cell Carcinoma · study director
- N/ANCT03481738 · Pyruvate Kinase Deficiency Global Longitudinal RegistryAgios Pharmaceuticals, Inc. · active not recruiting · Pyruvate Kinase Deficiency · study chair
- N/ANCT03428646 · Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)Regeneron Pharmaceuticals · active not recruiting · Dermatitis, Atopic · study director
- Ph1NCT03397329 · Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy AdultsAgios Pharmaceuticals, Inc. · completed · Healthy Volunteers · study chair
- Ph1NCT03250598 · Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian OriginAgios Pharmaceuticals, Inc. · completed · Healthy, Japanese, Non-Asian · study chair
- N/ANCT03247569 · Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo Company · completed · Atrial Fibrillation · study director
- N/ANCT03247582 · Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo Company · completed · Atrial Fibrillation · study director
- Ph4NCT03116828 · A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset SeizuresSumitomo Pharma America, Inc. · completed · Epilepsy With Partial On-set Seizures · study chair
- Ph1NCT03071770 · Japanese Bridging Study of Ivosidenib (AG-120) in Healthy SubjectsAgios Pharmaceuticals, Inc. · completed · Healthy · study chair
- N/ANCT03047083 · Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart ReviewAstellas Pharma Global Development, Inc. · completed · Acute Myeloid Leukemia (AML) · study director
- Ph3NCT02989857 · Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)Institut de Recherches Internationales Servier · completed · Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma · study chair
- N/ANCT02750813 · ACUVUE® OASYS® 1-DAY vs DAILIES TOTAL1®Alcon, a Novartis Company · completed · Refractive Error · study director
- Ph4NCT02746263 · Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe PainMallinckrodt · terminated · Acute Pain, Postoperative · study director
- Ph4NCT02715024 · Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder SymptomsAstellas Pharma Taiwan, Inc. · completed · Lower Urinary Tract Symptoms, Overactive Bladder, Benign Prostatic Hyperplasia (BPH) · study director
- Ph4NCT02616315 · Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric SurgeryTakeda · withdrawn · Weight Regain Post Bariatric Surgery · study director
- N/ANCT02605408 · Cataract Surgery in Indian Patients With or Without LenSx® LaserAlcon Research · withdrawn · Cataracts · study director
- N/ANCT02555787 · Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant PatientsAstellas Pharma Europe Ltd. · completed · Kidney Transplantation · study director
- N/ANCT02413333 · Clear Care® Plus vs. PeroxiClear™Alcon Research · completed · Refractive Error · study director
- N/ANCT02402127 · Lubricity Post-Wear - Competitive Lenses PilotAlcon Research · completed · Refractive Error · study director
- N/ANCT02396719 · A Real-World Registry to Investigate the Performance of LenSx® Laser in Chinese PatientsAlcon Research · completed · Cataracts · study director
- N/ANCT02320773 · A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical PracticeAstellas Pharma Europe Ltd. · completed · Urgency Incontinence, Urinary Bladder Overactive, Overactive Bladder · study director
- N/ANCT02293538 · Formula Identification (FID) 114657 in Contact Lens WearersAlcon Research · completed · Refractive Error · study director
- N/ANCT02189863 · Driving Simulator Study Comparing Two Modes of Presbyopic Correction With Contact LensesAlcon Research · completed · Presbyopia · study director
- N/ANCT02089191 · Tear Film Stability of DAILIES® AquaComfort Plus® Contact Lenses vs. MyDay® Daily Disposable Contact LensesAlcon Research · completed · Refractive Error · study director
- Ph4NCT01775397 · A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune SystemAstellas Pharma Europe Ltd. · terminated · Clostridium Difficile · study director
- Ph1NCT01681134 · A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male VolunteersAstellas Pharma Canada, Inc. · completed · Healthy · study director
- Ph1NCT01621542 · Clinical Study of WT2725 in Patients With Advanced MalignanciesSumitomo Pharma America, Inc. · completed · Cancer · study director
- Ph3NCT01539083 · Velcade (Bortezomib) Consolidation After TransplantJanssen Scientific Affairs, LLC · completed · Multiple Myeloma · study director
- Ph3NCT01336751 · Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination TreatmentSanofi · completed · Diabetes Mellitus, Type 2 · study director
- N/ANCT01290068 · Visual Outcomes After Cataract Surgery: Multifocal AcrySof® IQ ReSTOR® Intraocular Lenses Versus Monofocal Intraocular LensesAlcon Research · completed · Cataract · study director
- N/ANCT01257217 · A Comparison of Visual Function After Bilateral Implantation of Presbyopia-Correcting Intraocular Lenses (IOLs)Alcon Research · completed · Cataract · study director
- N/ANCT01200511 · Pilot Study of AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL)Alcon Research · completed · Cataract · study director
- N/ANCT01166659 · Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical TherapyTranscend Medical, Inc. · completed · Primary Open Angle Glaucoma (POAG) · study chair
- Ph4NCT01154153 · Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic RhinitisSanofi · completed · Rhinitis, Allergic, Perennial and/or Seasonal · study director
- N/ANCT01133002 · Canadian Outpatient VTE Management RegistrySanofi · completed · Medical Prevention Therapy · study director
- N/ANCT01110681 · Study to Evaluate Solesta for Treatment of Fecal IncontinenceGalderma R&D · completed · Fecal Incontinence · study director
- N/ANCT01085357 · Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract SurgeryTranscend Medical, Inc. · completed · Primary Open Angle Glaucoma (POAG), Cataract · study chair
- N/ANCT01076738 · Screening DIVA - Diffuse Vascular DiseaseSanofi · completed · Peripheral Vascular Diseases · study director
- Ph4NCT01024192 · Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIASanofi · completed · Sleep Disorders · study director
- Ph2NCT00988897 · Colorectal Cancer RECHALLENGESanofi · withdrawn · Colorectal Neoplasms · study director
- N/ANCT00931268 · Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With MacrolaneGalderma R&D · completed · Atrophy · study director
- Ph2NCT00808223 · Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe PsoriasisAstellas Pharma Inc · completed · Psoriasis · study director
- Ph4NCT00607087 · Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes MellitusSanofi · completed · Diabetes Mellitus, Type 1 · study director
- Ph3NCT00546507 · Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial IMika Pharma GmbH · completed · Osteoarthritis · study director
- Ph3NCT00546832 · Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial IIMika Pharma GmbH · completed · Osteoarthritis · study director
- N/ANCT00487214 · Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in GlaucomaAllergan · completed · Glaucoma, Open-Angle · study director
- Ph4NCT00457795 · 24-hour IOP-lowering Effect of Brimonidine 0.1%Allergan · completed · Open-angle Glaucoma, Ocular Hypertension · study director
- N/ANCT00454701 · Assessment and Tracking of Long-term Alefacept SafetyAstellas Pharma Inc · terminated · Psoriasis · study director
- Ph4NCT00440141 · Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%Allergan · completed · Glaucoma, Ocular Hypertension · study director
- Ph4NCT00440011 · Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%Allergan · completed · Glaucoma, Ocular Hypertension · study director
- Ph2NCT00404001 · Study of Oral MD-0727 Administered to Patients With Primary HypercholesterolemiaIronwood Pharmaceuticals, Inc. · completed · Hypercholesterolemia · study director
- Ph2NCT00402337 · Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic ConstipationIronwood Pharmaceuticals, Inc. · completed · Chronic Constipation · study director
- Ph4NCT00384085 · Insulin Glargine "All to Target" TrialSanofi · completed · Diabetes Mellitus, Type 2 · study director
- N/ANCT00342862 · AMEVIVE® Pregnancy RegistryAstellas Pharma Inc · terminated · Pregnancy · study director
- Ph4NCT00337558 · A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)Astellas Pharma Inc · completed · Overactive Bladder, Urinary Incontinence, Urge Incontinence · principal investigator
- Ph3NCT00330668 · Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 DeficiencyIpsen · terminated · Growth Disorders · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:35 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed